Icon

Dalvance - (500 mg/vial; Powder, Intravenous)

Dalbavancin Hydrochloride Abbvie
500 mg/vial; Powder, Intravenous
Less Than $1000 mn
None None
More Than 5
None
None None
DALVANCE is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms.
Yes
*** *** ******* ** *** **, ****. ** ****** ** ******** **** ** **** ** ****** ****** ****.
Dalvance Patent 1 Patent 2 Patent 3 Patent 4
** *******
  1. *** **, **** : * ****-** ** ***** *** ***** *** ***** *** *********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.